These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29372461)

  • 1. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.
    Kim HS; Ryu MH; Zang DY; Park SR; Han B; Kang WK; Rha SY; Jung M; Kim JS; Kang BW; Lee KH; Rho SY; Kim JH; Kim KC; Cho JW; Choi DR; Lim H; Kang HS; Soh JS; Kim MJ; Seo J; Kang YK
    Gastric Cancer; 2018 Sep; 21(5):802-810. PubMed ID: 29372461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
    Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
    Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
    Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
    Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
    Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of S-1 plus oxaliplatin 130 mg/m
    Kito Y; Machida N; Kawai S; Hamauchi S; Tsushima T; Todaka A; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Tsuji K; Doyama H; Haraguchi Y; Nakashima K; Kunieda K; Taku K; Mori K; Yasui H
    Int J Clin Oncol; 2018 Dec; 23(6):1084-1089. PubMed ID: 29931597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
    Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
    Yoo C; Han B; Kim HS; Kim KP; Kim D; Jeong JH; Lee JL; Kim TW; Kim JH; Choi DR; Ha HI; Seo J; Chang HM; Ryoo BY; Zang DY
    Cancer Res Treat; 2018 Oct; 50(4):1324-1330. PubMed ID: 29334603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
    Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
    Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
    Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
    BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
    Sato Y; Sagawa T; Ohnuma H; Hirakawa M; Takahashi Y; Hamaguchi K; Fujikawa K; Nobuoka T; Okamoto K; Miyamoto H; Muguruma N; Takemasa I; Takayama T
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):161-167. PubMed ID: 30406285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
    Jiang Z; Zhou A; Sun Y; Zhang W
    BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
    Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
    Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
    Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
    Zheng Y; Fang W; Mao C; Qian J; Zhao P; Zhang X; Jiang H; Zheng Y; Xu N
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):503-9. PubMed ID: 25038612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
    Chon HJ; Rha SY; Park HS; Shin SJ; Kim HS; Roh JK; Noh SH; Chung HC; Jeung HC
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):991-9. PubMed ID: 21327684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.